title: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
abstract: OBJECTIVE
  To quantify the association between olanzapine and diabetes.
  
  
  METHODS
  Population based nested case-control study.
  
  
  METHODS
  United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.
  
  
  METHODS
  19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls.
  
  
  METHODS
  Diagnosis and treatment of diabetes.
  
  
  RESULTS
  Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8).
  
  
  CONCLUSIONS
  Olanzapine is associated with a clinically important and significant increased risk of diabetes.
authors.affiliation: Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
authors.forename: Carol E
authors.initials: CE
authors.lastname: Koro
authors.forename: Donald O
authors.initials: DO
authors.lastname: Fedder
authors.forename: Gilbert J
authors.initials: GJ
authors.lastname: L'Italien
authors.forename: Sheila S
authors.initials: SS
authors.lastname: Weiss
authors.forename: Laurence S
authors.initials: LS
authors.lastname: Magder
authors.forename: Julie
authors.initials: J
authors.lastname: Kreyenbuhl
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Revicki
authors.forename: Robert W
authors.initials: RW
authors.lastname: Buchanan
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D016022:Case-Control Studies; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000139:chemically induced*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives; D012044:Regression Analysis; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine